Terren O'Connor

Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.

Cooley advised Red Tree Venture Capital on a $108 million oversubscribed Series B financing – co-led by RA Capital Management – in Bicara Therapeutics, a clinical-stage biotechnology company developing biologics for anti-tumor response.

Cooley advised Flexion Therapeutics, a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, on its agreement to sell to Pacira BioSciences. Lawyers Miguel Vega, Kevin Cooper, Sean Clayton and Matthew Silverman led the Cooley team advising Flexion.

Cooley advised Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics, on its agreement to sell to Bayer AG for a purchase price of $1.5 billion and up to $500 million in success-based milestone payments. Partners Barbara Borden and Karen Deschaine led the Cooley team advising Vividion.

Cooley advised Turning Point Therapeutics on its $191.5 million initial public offering of 10,637,500 shares of common stock. Turning Point Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol “TPTX,” is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Partners Charles Bair and Karen Anderson led the Cooley team.